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Abstract 26 
Objective: This study aimed to explore the effects of ambient temperature and relative humidity on insulin 27 
pharmacodynamics in adults with type 1 diabetes.  28 
Research Design:  A 3-way, cross-over, randomised study was performed in adults with type 1 diabetes 29 
mellitus (n=10). The pharmacodynamics profile of a single dose of short-acting insulin (insulin lispro) was 30 
investigated under three environmental conditions: i) temperature: 15°C and humidity: 10%, ii) temperature: 31 
30°C and humidity: 10%, and iii) temperature: 30°C and humidity: 60%, controlled in an environmental 32 
chamber. Euglycaemic glucose clamp technique ensured a constant blood glucose of 100 mg/dl (5.5 mmol/l). 33 
The following pharmacodynamic endpoints were calculated: maximum glucose infusion rate (GIRmax), time to 34 
GIRmax (tGIRmax), total area under the curve (AUC) for GIR from 0-6 hours (AUCGIR.0–6h), and partial AUCs 35 
(AUCGIR.0-1h, AUCGIR.0-2h and AUCGIR.2-6h).  36 
Results: Higher temperature (30
o
C) under 10% fixed humidity resulted in a greater GIRmax (p=0.04), a later 37 
tGIR.max (p=0.049) compared to lower temperature (15
o
C). Humidity did not affect any pharmacodynamic 38 
parameter. When the combined effects of temperature and humidity were explored, tGIR.max (p=0.008) occurred 39 
earlier with a lower late insulin pharmacodynamic effect (AUCGIR.2-6h, p=0.017) at temperature 15
o
C and 40 
humidity 10% compared to temperature 30
o
C and humidity 60%.  41 
Conclusions: High ambient temperature resulted in greater insulin peak effect compared to low ambient 42 
temperature, with the contribution of high relative humidity only apparent at high ambient temperature. This 43 
suggests that patients with type 1 diabetes mellitus entering higher environmental temperatures with or without 44 
high humidity could experience more hypoglycaemic events.   45 
 46 
Keywords: environmental conditions, ambient temperature, relative humidity, insulin pharmacodynamics, type 47 
1 diabetes mellitus 48 
  49 
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Introduction 50 
Type 1 diabetes mellitus is characterised by β-cell destruction and a lifelong requirement of exogenous insulin. 51 
Insulin requirements depend on insulin absorption from the injection site, the individual’s insulin sensitivity, 52 
body composition, inflammatory processes and environmental factors (1, 2). Evidence from epidemiological 53 
research suggests seasonal differences in HbA1c (3-5) and clinical onset of diabetes (6), with warmer 54 
temperature (summer) favouring lower HbA1c and lower incidence of diabetes compared to cooler 55 
temperatures (winter). Conversely, there is paucity of recent, well-controlled experimental studies employing 56 
technological advancements, such as an environmental chamber (7) using the gold standard glucose clamp 57 
technique (8) to investigate the effects of ambient temperature on insulin action, which could provide evidence 58 
of a cause-effect relationship. Nevertheless, there is increasing evidence of the local effects of temperature on 59 
insulin pharmacodynamics and pharmacokinetics. For instance, local warming of the injection site as a result of 60 
local skin massage (9), application of an insulin infusion site heating device (InsuPatch
TM
) (10-13), hot baths 61 
(14), or sauna exposure (15) has been shown to accelerate insulin absorption and improve insulin sensitivity in 62 
patients with diabetes, with these effects largely mediated by an increase in skin temperature, which results in 63 
an increased perfusion at the injection site.  64 
The effects of relative humidity on insulin pharmacodynamics and pharmacokinetics are largely unexplored. An 65 
epidemiological study conducted in the Mediterranean area suggested an increased prevalence of diabetes 66 
among the elderly who lived in islands with high relative environmental humidity when adjusted for ambient 67 
temperature (16). Notably, high relative humidity often occurs in the presence of high ambient temperature, 68 
making it challenging to unravel their individual effects (17). Individuals with diabetes appear to tolerate moist, 69 
warm air above 50% humidity less well than adults without diabetes (18). This may be due to the fact that high 70 
humidity when combined with high temperature decreases the rate of cooling of the human body leading to 71 
tiredness, exhaustion, reduction in alertness and potentially heat stroke (17, 19, 20), which may also affect 72 
glycaemic control.  73 
In order to assess the independent and combined effects of ambient temperature and relative humidity, this 74 
study evaluated the insulin pharmacodynamic profile following a single injection of a short-acting insulin 75 
analogue.  76 
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Research Design and Methods  77 
A single-centre, open label, 3-way cross-over study was performed in the Diabetes Research Centre at Hull 78 
Royal Infirmary in adults with type 1 diabetes mellitus  (n=10). All participants provided their written informed 79 
consent. The trial was approved by the Yorkshire & the Humber - Leeds West Research Ethics Committee 80 
(REC number: 14/YH/1129), registered at www.clinicaltrials.gov (NCT03102476) and conducted according to 81 
the Declaration of Helsinki. Individuals with type 1 diabetes mellitus were identified from the diabetes clinics 82 
and adverts placed in the Diabetes Centre at the Hull Royal Infirmary. Participants were included if they i) were 83 
males, ii) aged between 18-55 years, iii) had been diagnosed with type 1 diabetes mellitus, iv) had HbA1c ≤ 9.0 84 
% (75 mmol/mol) and a total insulin dose of < 1.2 U/kg/day, and v) had a body mass index (BMI) between 18.0 85 
and 28.0 kg/m
2
. Exclusion criteria were: i) known or suspected allergy to insulin, ii) recurrent major 86 
hypoglycaemia or hypoglycaemic unawareness within the previous 6 months, iii) clinically significant diabetes 87 
neuropathy, iv) participation in clinical trials involving investigational drugs within 3 months prior to screening 88 
and v) supine blood pressure at screening outside the range of 90-140 mmHg for systolic blood pressure or 50-89 
90 mmHg for diastolic blood pressure and/or resting supine heart rate outside the range 50 -90 beats per minute. 90 
The pharmacodynamic profile of the short-acting insulin lispro dosed at 0.2 units/kg was investigated under 91 
three environmental conditions for each subject: i) temperature: 15°C and humidity: 10%, ii) temperature: 30°C 92 
and humidity: 10%, and iii) temperature: 30°C and humidity: 60%. Participants attended six visits (Visits 1, 2a, 93 
2b, 3, 4 and 5). Visit 1, 2a and 5 were conducted in the Diabetes Centre, Hull Royal Infirmary, whereas Visits 94 
2b-4 were performed at the environmental chamber (Type SSR 60-20H, Design and Manufacture of 95 
Environmental Test Chambers, Gwent, Wales) located at the Department of Sport, Health & Exercise, 96 
University of Hull. During Visit 1, potential participants were screened against inclusion and exclusion criteria 97 
by medical history and clinical examination, routine blood tests (i.e., HbA1c) and an electrocardiogram (ECG). 98 
Visit 2a was performed >72 hours prior to Visit 2b to discuss and allow any arrangements in insulin regimens 99 
and lifestyle (diet, exercise). More specifically, participants were switched from insulin Lantus or Detemir to 100 
neutral protamine hagedorn (NPH) insulin 48 hours before Visit 2b. The NPH insulin was stopped 22 hours 101 
before Visit 2b-4, except for short acting insulin analogues, which were stopped 6-8 hours before that visit. 102 
Visits 2b-4 were the main experimental days, during which different environmental conditions were controlled 103 
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and the euglycaemic clamp was performed. Participants were weighed without shoes on a weighing scale 104 
(Marsden Weighing Machine Group Ltd, UK), height was taken barefoot using a wall-mounted stadiometer and 105 
BMI was calculated as body mass (kg) divided by the height squared (m
2
). Blood pressure was measured using 106 
a sphygmomanometer (Datascope Duo Masimo Set, Mindray Ltd, UK). Blood glucose was continuously 107 
monitored pre-administration and for the duration of the clamp procedures. Standard safety parameters 108 
including blood pressure, heart rate and temperature were performed every 30 minutes throughout the study. 109 
Three to twenty-one days were allowed between Visit 2a, 3 and 4. Visit 5 was performed as a follow-up 110 
examination within 14 days of the last experimental day (Visit 2b, 3 or 4) and included physical examination 111 
and glycemic management review.  112 
 113 
Euglycaemic glucose clamp procedure  114 
Prior to the euglycaemic glucose clamp, all participants fasted overnight and for the duration of the 6-hour 115 
procedure. Water was allowed as required. In the clinic room, with the participant in a comfortable supine or 116 
semi-supine state, vital signs were recorded before two cannulas were inserted, one in the hand or forearm to be 117 
used for venous sampling, with the hand heated to 55°C throughout the clamp allowing arterialisation of the 118 
venous blood (21). The second cannula was inserted on the opposite arm situated in the cubital fossa to be used 119 
for a variable infusion of insulin [15 units of Humulin S in 49mL saline and 1mL of participants own blood] or 120 
glucose (20% in saline). The infusion was initiated with a target blood glucose level of 5.5mmol/L (100mg/dL) 121 
± 20% for 30-60 min prior to the participant being relocated to the environmental chamber where baseline 122 
glucose levels were taken followed by the injection of insulin lispro (NovoFine 32G Tip etw 0.23/0.25 x 6mm, 123 
Novo Nordisk A/S, Denmark) on the left shoulder of the participants, equal to time 0.  124 
In the environmental chamber, subjects were allowed to wear light clothes to mimic real life situations. The 125 
variable glucose infusion was used to maintain the target blood glucose level of 5.5mmol/L (100mg/dL) ± 20% 126 
guided by an algorithm (22) and the participants’ measured blood glucose concentration in the preceding 5 min. 127 
The blood glucose concentrations were measured by a glucose analyser (HemoCue® glucose 201+) and 128 
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recorded together with the glucose infusion rate every 5–10 min throughout the clamp. Upon completion of the 129 
clamp procedure, vital signs were checked and lunch was provided before discharge.  130 
Biochemical analysis  131 
Venous blood samples were collected at Visit 1 as part of screening procedures. Plasma blood samples were 132 
centrifuged at 3,500×G for 15min at 5°C and analysed for HbA1c on a Menarini Diagnostics HB9210 premier 133 
(A.Menarini Diagnostics Ltd., Winnersh-Wokingham, UK). 134 
Statistical analysis 135 
The exogenous glucose infusion rate (GIR) was analysed every 5 to 10 minutes throughout the clamp. A 136 
weighted local regression technique (LOESS) with a smoothing factor (SF) of 0.1 for the calculation of time-137 
related parameters and maximum GIR in accordance with previous studies that had investigated the 138 
pharmacodynamics of short-acting insulin (23). The pharmacodynamic endpoints calculated for each clamp 139 
study visit (Visit 2b, 3 and 4) were the maximum glucose infusion rate (GIRmax) and time to maximum glucose 140 
infusion rate (tGIRmax). In addition to total area under the curve (AUC) for GIR from 0 to 6 hours min 141 
(AUCGIR.0–6h), partial AUCs from 0-1 hour, 0-2 hours (AUCGIR.0-1h), 0-6 hours (AUCGIR.0-2h) and 2-6 hours 142 
(AUCGIR.2-6h) following the insulin injection were also calculated to determine early and late insulin action. A 143 
two-way ANOVA with temperature, humidity and their interaction as fixed effects and the subject as random 144 
effect was used for AUCGIR.0-1h, AUCGIR.0-2h, AUCGIR.0-6h, AUCGIR.2-6h, GIRmax (SF=0.1) and tGIR.max(SF=0.1). Data are 145 
presented as mean (1SD) and statistical significance was set at p≤ 0.05. For graphical presentation (Figure 1) a 146 
SF of 0.3 was used and 10 data points with GIR-values of nearly 40 mg/kg/min in one subject were excluded in 147 
order to minimise random GIR-fluctuations. Statistical analysis was conducted using SAS, version 9.4.  148 
Results 149 
The demographic and clinical characteristics of the adults with type 1 diabetes mellitus at baseline are presented 150 
in Table 1. 151 
The independent effects of ambient temperature 152 
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As illustrated in Figure 1 and Table 2, at temperature 30
o
C and humidity 10% the time-action curve of insulin 153 
was shifted to the right, with a later tGIR.max (p=0.049) and a significantly greater GIRmax (p=0.04), compared to 154 
the condition at 15
o
C temperature and same level of humidity (10%). Although AUCGIR.0-1h, AUCGIR.0-2h and 155 
AUCGIR.0-6h did not differ significantly between the conditions with different temperatures, there was a trend 156 
towards a higher AUCGIR 2-6h, when comparing temperature 30
o
C vs. temperature 15
o
C (p=0.08) (Table 2).  157 
The independent effects of relative humidity 158 
There was no effect of humidity on insulin pharmacodynamics, as indicated by no significant differences in 159 
GIRmax, tGIR.max and AUCs for the time-action profile between the condition at temperature 30
o
C and humidity 160 
10% vs. the condition at temperature 30
o
C and humidity 60% (p values between 0.21 and 0.95) (Table 2).  161 
The combined effects of ambient temperature and relative humidity  162 
When exploring the combined effects of temperature and humidity, tGIR.max (SF=0.1) (p=0.008) occurred on 163 
average 44 min earlier (AUCGIR.2-6h, p=0.017) at temperature 15
o
C and humidity 10% compared to temperature 164 
30
o
C and humidity 60% (Figure 1, Table 2) with less glucose that needed to be infused at lower temperature 165 
and humidity, but no differences were seen for early (AUCGIR.0-1h, p=0.48, AUCGIR.0-2h, p=0.87) and overall 166 
(AUCGIR.0-6h, p=0.48) effects on insulin action (Table 2). 167 
 168 
Discussion  169 
By using the glucose clamp technique, the present study demonstrated that sudden changes in environmental 170 
conditions affect short-acting insulin analogue (insulin lispro) pharmacodynamics in adult men with type 1 171 
diabetes mellitus. In response to higher temperature (30
o
C vs. 15
o 
C) under fixed humidity there was a greater 172 
GIRmax and a trend towards a greater AUCGIR2-6h. High humidity affected insulin pharmacodynamics only when 173 
it was combined with high temperature. The mean time to GIRmax was prolonged under 30
o
C temperature and 174 
10 or 60% humidity compared to 15
o 
C and 10% humidity and the GIRmax and the late AUC (AUCGIR2-6h) were 175 
greater, suggesting enhanced insulin absorption and peak effect.  176 
Page 8 of 17
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
A limited number of studies have simulated the effects of environmental conditions on insulin 177 
pharmacodynamics. Ronnemaa & Koivisto investigated the acute effects of ambient temperature (10
o 
C vs. 30
o
 178 
C) with and without exercise on insulin absorption and postprandial glycaemia in patients with type 1 diabetes 179 
mellitus, but in a different experimental protocol without using a glucose clamp. They showed no significant 180 
effect of ambient temperature on total blood glucose AUC, calculated using glucose values from the time of 181 
insulin injection to the end of the study (195 min) (7), but significant effects were revealed for partial AUC 182 
from 80 min post injection to 195 min. These results are in accord with the results of the present study where 183 
there were no significant differences between the experimental conditions at 15
o
C and 30
o
C for AUCGIR 0-6h, but 184 
a trend towards a greater AUCGIR 0-6h with a higher temperature. The same study (7) also assessed insulin 185 
pharmacokinetic parameters and showed a 3- to 5-fold higher AUC for plasma free insulin at 30
o
C than at 10
o
C, 186 
regardless of exercise. We cannot provide comparative data on these aspects, given that our study is limited to 187 
insulin pharcodynamics rather than its pharmacokinetic profile. Furthermore, it is more challenging to detect 188 
differences in pharmacodynamic parameters than in pharmacokinetic parameters, as pharmacodynamic 189 
parameters are often characterised by greater variability and, therefore, the pharmacokinetic results would be 190 
expected to be in line with the pharmacodynamic findings in our study. 191 
Exposure to higher temperatures compared to the high temperature (30
o
C) investigated in this work has been 192 
shown to have favourable effects on time-action profiles of different types of insulin analogues. It is reported 193 
that sauna exposure (twice for 25 min at temperature 85°C and relative humidity 30-50%) accelerated insulin 194 
absorption by 110% (assessed by measuring the disappearance rate of 
125
I-labelled rapid-acting insulin) 195 
compared with room temperature in 8 participants with diabetes (type 1 diabetes mellitus , n=7; type 2 diabetes 196 
mellitus, n=1) (15). Hot baths (water temperature ≥ 40
o
C) increased serum insulin levels 90 minutes after 197 
injection (14). Other studies have shown temperature effects on insulin pharmacodynamics, when heat is 198 
applied locally at the site of injection (10-13, 24). When a local heating device at the injection site (InsuPatchTM) 199 
was utilised to achieve skin temperature of 38.5
o
C, the time to reach maximal action of a 0.2 U/kg bolus dose of 200 
insulin aspart decreased from 125 min to 90 min in adults with type 1 diabetes mellitus (13) and similarly at 201 
40°C (12). Meal tolerance test studies showed that local heat resulted in significant reductions in the time to 202 
maximal insulin action and lower postprandial excursion in patients with type 1 diabetes mellitus (11, 24). 203 
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These data suggest that high ambient temperature increases subcutaneous insulin absorption due to effects on 204 
blood perfusion at the injection site. In line with these findings, we showed enhanced insulin action and a 205 
prolonged time to maximum infusion rate with higher temperature compared to lower temperature. The latter 206 
findings about the time to maximum infusion rate can be explained at least partially by a greater GIRmax 207 
observed in the condition with the higher temperature (i.e., a greater GIRmax is expected to be reached later). 208 
The discrepancies between this and previous studies may be largely due to differences in the exposure to the 209 
heat (i.e., extent, locality and duration). Although measurements of skin temperature were not available in this 210 
study, these results are suggestive of a delayed thermoregulatory effect on subcutaneous tissue in the hotter 211 
environment (30
o
C), which may explain the absence of earlier changes in the environment surrounding the 212 
insulin depot.  213 
Conversely, we observed a shorter mean time to GIRmax under 15
o
C and 10% humidity compared to 30
o
C 214 
temperature and 10% humidity and a lower GIRmax and late AUC (AUCGIR2-6h). These results are in agreement 215 
with a previous study by Vallerand et al. which showed that in response to an intravenous glucose tolerance test 216 
under nude exposure to cold (3h at 10
o
C) plasma glucose area under the curve was lower and plasma glucose 217 
levels returned to baseline levels within an hour compared to 2h under warm exposure (3h at 29
o
C) despite low 218 
insulin levels and enhanced carbohydrate metabolism (25). It is speculated that the marked effects of cold 219 
exposure may due to enhanced insulin sensitivity and/or increased responsiveness for glucose uptake in 220 
peripheral tissues such as skeletal muscles (25-27), although in the current study we cannot provide further 221 
insight into these mechanisms, given that subcutaneous insulin was used and therefore, other factors (e.g., 222 
visceral and subcutaneous tissues) may have differentially effect the pharmacodynamics parameters.  223 
Short term exposure to different levels of relative humidity (10 and 60%) under fixed temperature had no effect 224 
on the insulin time-action profile. However, exposure to high relative humidity in combination with high 225 
ambient temperature resulted in a prolonged time to GIRmax and a greater insulin pharmacodynamic effect 226 
compared to the responses to the low temperature low humidity condition, suggesting that high humidity may 227 
augment the high temperature effect on enhanced insulin absorption from the injection site, but has little effect 228 
in its own right. 229 
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In conclusion, high ambient temperature resulted in greater insulin peak effect compared to low ambient 230 
temperature, with the contribution of high relative humidity to insulin absorption only apparent at high ambient 231 
temperature. This suggests that patients with type 1 diabetes mellitus entering environmental higher 232 
temperatures with or without high humidity could experience more hypoglycaemic events.   233 
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Figure Legends  304 
Figure 1. Average glucose infusion rate (GIR) (mg/kg/min) values to maintain euglycaemia under different 305 
environmental conditions; T15/H10: temperature 15
o
C and humidity 10%, T30/H10: temperature 30
o
C and 306 
humidity 10% and T30/H60: temperature 30
o
C and humidity 60%.    307 
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Table 1: Baseline characteristics of the participants (n=10). 308 
 Adults with Type 1 diabetes (n=10) 
Age (years) 28.3±7.1 
Weight (kg) 74.1±12 
Height (cm) 170.6±5.7 
BMI (kg/m
2
) 24.3±2.9 
Systolic BP (mmHg) 124.2±9.4 
Diastolic BP (mmHg) 75.6±7.5 
Duration of diabetes (years) 18.8±7.7 
HbA1c (%) 7.9±0.8 
HbA1c (mmol/mol) 63±6.7   
Data are presented as means ±1SD. BMI body mass index, BP blood pressure, HDL high density lipoprotein, 309 
LDL low density lipoprotein, HbA1C Haemoglobin A1c.  310 
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Table 2: AUCGIR for 0-1h, 0-2h, 0-6h and 2-6 h, GIRmax and tGIR.max 
 AUCGIR.0-1h (mg/kg) AUCGIR.0-2h (mg/kg) AUCGIR.0-6h (mg/kg) 
 Mean±SD Min-Max Mean±SD Min-Max Mean±SD Min-Max 
T15/H10 136±251 0-835 347±496 12-1727 815±764 260-2823 
T30/H10 94±65 0-180 314±162 29-537 825±453 37-1501 
T30/H60 85±78 0-233 325±172 101-626 977±435 347-1606 
P values T15/H10 vs. T30/H10 0.56 T15/H10 vs. T30/H10 0.81 T15/H10 vs. T30/H10 0.96 
T15/H10 vs. T30/H60 0.48 T15/H10 vs. T30/H60 0.87 T15/H10 vs. T30/H60 0.48 
T30/H10 vs. T30/H60 0.90 T30/H10 vs. T30/H60 0.94 T30/H10 vs. T30/H60 0.51 
 AUCGIR.2-6h (mg/kg) GIRmax  (mg/kg/min) tGIR.max (min) 
 Mean±SD Min-Max Mean±SD Min-Max Mean±SD Min-Max 
T15/H10 467±319 114-1096 7.4±7.6 2.3-29 107±61.8 10-205 
T30/H10 511±965 8-965 11.1±6.5 1.2-22 137±63 18-217 
T30/H60 652±1196 140-1196 8.5±2.9 4-13 151±99 10-319 
p-values  T15/H10 vs. T30/H10 0.08 T15/H10 vs. T30/H10 0.04 T15/H10 vs. T30/H10 0.049 
T15/H10 vs. T30/H60 0.008 T15/H10 vs. T30/H60 0.57 T15/H10 vs. T30/H60 0.017 
T30/H10 vs. T30/H60 0.22 T30/H10 vs. T30/H60 0.21 T30/H10 vs. T30/H60 0.65 
Data are presented as mean± 1SD, (min) and maximum(max) T15/H10: Temperature 15
o
C/Humidity 10%, T30/H10: Temperature 30
o
 C/Humidity 10%, T30/H60: 
Temperature 30
o
 C/Humidity 60%, AUC: area under the curve, GIR: glucose infusion rate, GIRmax: maximum glucose infusion rate, tGIR.max: time to maximum 
glucose infusion rate. P-values <0.05 are indicated in bold italics. Statistical analysis was performed on the unsmoothed data.
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